Fennec Pharmaceuticals Partners with Tampa General to Study PEDMARK® in Adult Cancer Patients
FENC sits 75% above its 52-week low of $4.68.
Summary
Fennec Pharmaceuticals announced a clinical research collaboration with Tampa General Hospital Cancer Institute. The study will evaluate the real-world clinical utility of PEDMARK® (sodium thiosulfate injection) in reducing ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin chemotherapy. This collaboration follows Fennec's recent announcement of positive real-world data for PEDMARK® in adult head and neck cancer patients, indicating a continued focus on expanding the evidence base and market for their key product. While PEDMARK® is currently approved for pediatric patients and recommended for AYA patients, this collaboration aims to generate further real-world evidence for its use in a broader adult population. This can support wider adoption, inform future clinical research, and potentially lead to label expansion or updated treatment guidelines, strengthening the long-term commercial prospects of PEDMARK®. Traders will monitor the progress and results of this study, as positive outcomes could further solidify PEDMARK®'s position in the market and expand its addressable patient population.
At the time of this announcement, FENC was trading at $8.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $273.1M. The 52-week trading range was $4.68 to $9.92. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.